Guidelines for the Use of Immunoglobulin Therapy for Primary Immune Deficiency and Solid Organ Transplantation

Transfusion Medicine Reviews

Volumn 24, Issue SUPPL. 1, 2010, Pages

  Nahirniak, Susan ^a   Hume, Heather A ^b  

^a National Advisory Committee on Blood and Blood Products   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN;

ACUTE GRAFT REJECTION; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; EDITORIAL; GRAFT REJECTION; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; NEUROLOGIC DISEASE; ORGAN TRANSPLANTATION; PARTICIPATORY MANAGEMENT; PRACTICE GUIDELINE; THROMBOEMBOLISM;

HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; ORGAN TRANSPLANTATION; PERIODICALS AS TOPIC; PRACTICE GUIDELINES AS TOPIC;

EID: 71149102844     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.09.009     Document Type: Editorial

References (8)

1. Anderson D., Ali K., Blanchette V., et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 21 suppl 1 (2007) S9-S56
2. Feasby T., Banwell B., Benstead T., et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 21 suppl 1 (2007) S57-S107
3. Hume H.A., and Anderson D.R. Guidelines for the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 21 suppl 1 (2007) S1-S2
4. (2009). www.blood.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/resources/Fracti onation/$file/1_00-05_en.pdf Accessed August
5. Hughes R.A.C., Donofrio P., Bril V., et al. Intravenous immune globulin (10% caprylate chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomized placebo controlled trial. Lancet Neurol 7 (2008) 136-144
6. Pierce L.R., and Jain N. Risks associated with the use of intravenous immunoglobulin. Trans Med Rev 17 (2003) 241-251
7. Hamrock D.J. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 6 (2006) 535-542
8. Canadian Task Force on Preventative Health Care Levels of Evidence and Recommendation Guide. Available at http://www.ctfphc.org/. (Last accessed August 2009).